Life sciences is one of the most heavily regulated industries in Canada, and with this regulatory environment come administrative and constitutional challenges. But what strategies and practical guidance should life sciences companies consider when navigating a changing regulatory environment? What can we learn about public law and the scope of agency oversight over life sciences companies?
Partners Teresa Reguly, Yael Bienenstock and Andrew Bernstein give us a sneak peek into the issues at play in their upcoming webinar on September 24 on public law for life sciences companies, including:
- determining the scope of an agency’s oversight and whether they are acting within its authority;
- public law issues that can arise if an agency updates or creates a policy; and
- challenging the designation of a biosimilar as interchangeable.
Register for the upcoming webinar here and play the teaser video below for a preview of what is sure to be an engaging discussion.
To discuss these issues, please contact the author(s).
This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.
For permission to republish this or any other publication, contact Janelle Weed.
© 2020 by Torys LLP.
All rights reserved.